Joannes F M Jacobs

List of Publications by Year
in descending order

76 papers	3,889 citations	147566 31 h-index	123241 61 g-index
76 all docs	76 docs citations	76 times ranked	6313 citing authors

#	Article	IF	Citations
1	PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. Journal of Immunotherapy, 2012, 35, 169-178.	1.2	269
2	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncology, The, 2012, 13, e32-e42.	5.1	219
3	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. Clinical Cancer Research, 2010, 16, 5067-5078.	3.2	212
4	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016, 22, 2155-2166.	3.2	211
5	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology, 2009, 11, 394-402.	0.6	203
6	Prognostic significance and mechanism of Treg infiltration in human brain tumors. Journal of Neuroimmunology, 2010, 225, 195-199.	1.1	180
7	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research, 2009, 15, 2531-2540.	3.2	172
8	Route of Administration Modulates the Induction of Dendritic Cell Vaccineâ€“Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	3.2	158
9	Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunology, Immunotherapy, 2008, 57, 1589-1597.	2.0	141
10	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cellâ€“Based Vaccination. Cancer Research, 2013, 73, 19-29.	0.4	131
11	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. International Journal of Cancer, 2011, 129, 507-512.	2.3	120
12	Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nature Communications, 2018, 9, 3317.	5.8	116
13	Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1095-104.	1.4	102
14	Tollâ€like receptor signalling on Tregs: to suppress or not to suppress?. Immunology, 2008, 124, 445-452.	2.0	87
15	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	3.2	86
16	Elimination of regulatory T cells is essential for an effective vaccination with tumor lysateâ€pulsed dendritic cells in a murine glioma model. International Journal of Cancer, 2008, 122, 1794-1802.	2.3	78
17	Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. International Journal of Cancer, 2007, 120, 67-74.	2.3	70
18	Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. Clinical Cancer Research, 2011, 17, 841-848.	3.2	70

#	Article	IF	Citations
19	Anaphylaxis from Passive Transfer of Peanut Allergen in a Blood Product. New England Journal of Medicine, 2011, 364, 1981-1982.	13.9	67
20	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3â€²-fluoro-3â€²-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	3.3	65
21	Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clinical Chemistry and Laboratory Medicine, 2016, 54, 1105-9.	1.4	65
22	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. OncoImmunology, 2015, 4, e1019197.	2.1	55
23	Long-lasting multifunctional CD8⁺T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. OncoImmunology, 2016, 5, e1067745.	2.1	55
24	Antigen excess in modern immunoassays: To anticipate on the unexpected. Autoimmunity Reviews, 2015, 14, 160-167.	2.5	51
25	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cellâ€“Based Vaccination in Metastatic Melanoma. Cancer Research, 2012, 72, 6102-6110.	0.4	50
26	The role of interleukin-1 beta in the pathophysiology of Schnitzlerâ€™s syndrome. Arthritis Research and Therapy, 2015, 17, 187.	1.6	45
27	N Latex FLC serum free light-chain assays in patients with renal impairment. Clinical Chemistry and Laboratory Medicine, 2014, 52, 853-9.	1.4	38
28	Is accuracy of serum free light chain measurement achievable?. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1021-30.	1.4	38
29	Overestimation of Serum Îº Free Light Chain Concentration by Immunonephelometry. Clinical Chemistry, 2010, 56, 1188-1190.	1.5	37
30	An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clinical Chemistry and Laboratory Medicine, 2020, 58, 533-546.	1.4	36
31	Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies. Journal of Proteome Research, 2018, 17, 1326-1333.	1.8	32
32	An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clinical Chemistry and Laboratory Medicine, 2020, 58, 547-559.	1.4	32
33	Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunology, Immunotherapy, 2009, 58, 145-151.	2.0	29
34	Regulation of MYCNexpression in human neuroblastoma cells. BMC Cancer, 2009, 9, 239.	1.1	28
35	Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination. Clinical Cancer Research, 2011, 17, 4541-4549.	3.2	28
36	Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. Clinical Biochemistry, 2018, 51, 72-79.	0.8	28

#	Article	IF	Citations
37	Relatively Restricted Migration of Polyclonal IgG4 May Mimic a Monoclonal Gammopathy in IgG4-Related Disease. American Journal of Clinical Pathology, 2014, 142, 76-81.	0.4	27
38	Quantitative Measurement of Immunoglobulins and Free Light Chains Using Mass Spectrometry. Analytical Chemistry, 2015, 87, 8268-8274.	3.2	27
39	Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. Clinical Chemistry and Laboratory Medicine, 2018, 56, 312-322.	1.4	26
40	Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum Îº and Î» immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clinical Chemistry and Laboratory Medicine, 2017, 55, 424-434.	1.4	25
41	Selective cancer-germline gene expression in pediatric brain tumors. Journal of Neuro-Oncology, 2008, 88, 273-280.	1.4	24
42	Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunology, Immunotherapy, 2012, 61, 2003-2011.	2.0	24
43	Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow. Clinical Chemistry, 2021, 67, 1689-1698.	1.5	24
44	Standardization and harmonization of autoimmune diagnostics. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1563-1567.	1.4	22
45	Effect of sample dilution on two free light chain nephelometric assays. Clinica Chimica Acta, 2012, 413, 1708-1709.	0.5	21
46	Method comparison of four clinically available assays for serum free light chain analysis. Clinical Chemistry and Laboratory Medicine, 2019, 58, 85-94.	1.4	21
47	Fast, robust and high-resolution glycosylation profiling of intact monoclonal IgG antibodies using nanoLC-chip-QTOF. Clinica Chimica Acta, 2016, 461, 90-97.	0.5	20
48	Simultaneous Presence of Non- and Highly Mutated Keyhole Limpet Hemocyanin (KLH)-Specific Plasmablasts Early after Primary KLH Immunization Suggests Cross-Reactive Memory B Cell Activation. Journal of Immunology, 2018, 200, 3981-3992.	0.4	18
49	Allogeneic and autologous serum eye drops: a pilot doubleâ€blind randomized crossover trial. Acta Ophthalmologica, 2021, 99, 837-842.	0.6	17
50	Antiâ€<scp>SSA</scp> antibodies are present in immunoglobulin preparations. Transfusion, 2015, 55, 832-837.	0.8	16
51	Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients. Scientific Reports, 2017, 7, 43486.	1.6	16
52	Changes in peripheral immune cell numbers and functions in octogenarian walkers â€“ an acute exercise study. Immunity and Ageing, 2017, 14, 5.	1.8	15
53	Integrating Serum Protein Electrophoresis with Mass Spectrometry, A New Workflow for M-Protein Detection and Quantification. Journal of Proteome Research, 2020, 19, 2845-2853.	1.8	15
54	Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1963-1971.	1.4	14

#	Article	IF	Citations
55	Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, e232-e234.	1.4	13
56	Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma. Clinical Chemistry, 2021, 67, 867-875.	1.5	12
57	Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatric Blood and Cancer, 2007, 49, 924-927.	0.8	10
58	The Role of FcRn in the Pharmacokinetics of Biologics in Patients With Multiple Myeloma. Clinical Pharmacology and Therapeutics, 2017, 102, 903-904.	2.3	9
59	Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma. HemaSphere, 2020, 4, e413.	1.2	8
60	Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary?. Journal of Nephrology, 2020, 33, 611-617.	0.9	8
61	Severe exacerbation of Crohnâ€™s disease during sunitinib treatment. European Journal of Gastroenterology and Hepatology, 2014, 26, 234-236.	0.8	7
62	Analytical validation of the Hevylite assays for M-protein quantification. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1169-1175.	1.4	7
63	Assessment of serum free light chain levels in healthy adults immediately after marathon running. Clinical Chemistry and Laboratory Medicine, 2016, 54, 459-65.	1.4	6
64	Plasma therapy leads to an increase in functional IgA and IgM concentration in the blood and saliva of a patient with X-linked agammaglobulinemia. Journal of Translational Medicine, 2019, 17, 174.	1.8	5
65	External quality assessment of M-protein diagnostics: a realistic impression of the accuracy and precision of M-protein quantification. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1063-1068.	1.4	5
66	Dendritic Cells as Vaccines: Key Regulators of Tolerance and Immunity. Mediators of Inflammation, 2016, 2016, 1-2.	1.4	4
67	FLC polymerization: Another hurdle towards standardization of FLC measurements. Clinica Chimica Acta, 2021, 515, 42-43.	0.5	4
68	Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy. OncoImmunology, 2014, 3, e27219.	2.1	3
69	The impact of exercise on the variation of serum free light chains. Clinical Chemistry and Laboratory Medicine, 2014, 52, e239-42.	1.4	3
70	Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. Human Vaccines and Immunotherapeutics, 2015, 11, 1634-1640.	1.4	2
71	Broad Bands Observed in Serum Electrophoresis Should Not Be Taken Lightly. Clinical Chemistry, 2019, 65, 618-621.	1.5	2
72	Method comparison of three serum free light chain assays on the Roche Cobas 6000 c501 chemistry analyzer. Clinical Chemistry and Laboratory Medicine, 2022, 60, 379-385.	1.4	2

#	Article	IF	Citations
73	What is Your Guess? Detecting Only Light Chains, Now What?. Clinical Chemistry, 2010, 56, 1368-1368.	1.5	1
74	Response to: Interference of daratumumab on the serum protein electrophoresis. Clinical Chemistry and Laboratory Medicine, 2017, 55, e29-e30.	1.4	1
75	Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow. Blood, 2020, 136, 9-9.	0.6	1
76	Reply to Berlanga et al. (DOI 10.1515/cclm-2014-0420). Clinical Chemistry and Laboratory Medicine, 2014, 52, e247-e248.	1.4	0